Enhancing capacity for Phase 1 trials in Uganda (CAPA-CT Project)

There are no licensed therapies for viral hemorrhagic fevers. There is an urgent need for effective drug therapies for symptomatic patients with Ebola virus disease and other viral hemorrhagic fevers. The Capa-CT project aims to enhance capacity for the conduct of Phase 1 clinical trials of therapeutic agents at the Infectious Diseases Institute (IDI), Makerere University College of Health Sciences, Kampala, Uganda.

Over a 2 year period, the Capa-CT project will:

• Train clinical trial and support staff at IDI to conduct early phase clinical trials.
• Deploy equipment and tools to enhance performance of trained staff at IDI.
• Implement an enhanced quality system for clinical trial and support services processes at IDI.
• Establish robust local referral hospital linkages and facility transfer arrangements.

The project builds on long-standing capacity for anti-infective pharmacology research at IDI. Linkages to stakeholders in drug development will be strengthened and best practices and lessons that are learned will be shared with partner organizations.